After a slew of reports of serious complications associated with the multiple sclerosis drug Zinbryta, its manufacturers have issued a Zinbryta withdrawal, recalling the drug from the market. The Zinbryta withdrawal came after reports of serious complications including brain inflammation, along with the dangerous skin disease Stevens Johnson syndrome. If you or someone you love has suffered from Zinbryta side effects like brain inflammation, you may be able to pursue litigation.

Basics of Zinbryta

Zinbryta (also known by its generic name, daclizumab) is a new multiple sclerosis drug jointly manufactured by pharmaceutical companies Biogen and Abbvie. Zinbryta was released onto the market after its approval by the U.S. Food and Drug Administration (FDA) on May 27, 2016.

Multiple sclerosis (MS) is a condition that involves the immune system attacking and damaging the protections around the central nervous system. Zinbryta’s introduction to the market was meant as an additional option for patients who have not found other MS medications effective.

Zinbryta Side Effects

Unfortunately, Zinbryta has been associated with a number of serious side effects. One of the most significant of these complications is Zinbryta brain inflammation. Brain tissue inflammation, also known as encephalitis, is often caused by a bacterial infection, viral infection, or immune system disorder.

Symptoms of Zinbryta brain inflammation are similar to those of the flu, and can last for two or even three weeks. Symptoms include muscle pain, fatigue, fever, nausea or vomiting, irritability, light sensitivity, headache, seizures, and more.

Other major Zinbryta side effects include:

• Encephalitis and other immune reactions
• Liver failure and injury
• Stevens Johnson syndrome

The Zinbryta Withdrawal

After receiving reports from patients over a slew of side effects, Zinbryta’s manufacturers issued a voluntary Zinbryta withdrawal of their multiple sclerosis drug. Biogren and Abbvie announced the recall on March 2, 2018, saying that they would be removing Zinbryta from the global market because of reports of Zinbryta brain inflammation, including encephalitis and meningoencephalitis.

The FDA has also been made aware of the complications linked with Zinbryta, but the manufacturers’ Zinbryta withdrawal was voluntary. The FDA has stated since the recall that it is now working closely with the manufacturers, Biogen and Abbvie, “to help ensure a well-organized withdrawal from the market in the United States, and to ensure that healthcare professionals have the information they need to carefully transition their patients using Zinbryta to another treatment.”

The Zinbryta withdrawal was relatively relaxed, as the drug wasn’t pulled immediately. The FDA announced that “no new patients will start taking Zinbryta or participate in clinical studies,” and the drug was available for use until April 30, 2018. Now, the drug is no longer available.

Filing a Lawsuit After Zinbryta Withdrawal

If you or someone you love has suffered from Zinbryta brain inflammation or other side effects after using this multiple sclerosis drug, you may be able to file a lawsuit. Filing a lawsuit cannot take away the pain and suffering caused by Zinbryta brain inflammation and other major complications, but it can help to alleviate the financial burden caused by medical expenses and lost wages.